Organization
Compass Oncology
4 abstracts
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
Comparison of real-world mortality data among patients with glioblastoma (GBM) and metastatic pancreatic cancer (mPC) treated in the community oncology setting.Org: Compass Oncology, Vancouver, WA, Ontada, The Woodlands, TX, Irving, TX,
Abstract
Real world treatment patterns and survival by germline BRCA (gBRCA) mutation status in patients with HER2-negative early breast cancer (eBC) in the US community oncology setting: A retrospective observational study.Org: Compass Oncology, Merck & Co., Inc., Ontada, Memorial Sloan Kettering Cancer Center, AstraZeneca,
Abstract
Assessment of genomic profiling in patients with colorectal cancer treated in community oncology practices.Org: Compass Oncology, Ontada,